The impact of COVID-19 on human beings around the world has been hard, immense and unremitting so far. The threat from this pandemic to people with acute or chronic medical conditions and weakened immune systems, such as cancer patients, is high. The FDA Oncology Center of Excellence has issued a statement in this connection, reaffirming its commitment to keep the unique needs of patients with cancer as a top priority.
The National Cancer Institute has asked patients with cancer to follow the CDC’s advice on regular washing of hands and keeping hands away from touching one’s face. Other precautions include avoiding travel and crowds and staying at home as much as possible and keeping several weeks of medication and supplies available. Such additional actions are expected to help keep people, at high risk from developing serious complications from COVID-19, safe.
Current Priorities:
Here are the priorities laid out when working to address the critical issues being faced by this patient population:
The communication also stresses on the need to schedule ongoing treatment appointments, only after carefully weighing the need against the possibility of exposing the patient to a risk of contracting COVID-19, as per the regulatory authority.
Lumiseek offers an innovative technology platform which enables collaboration between all the oncology-focused stakeholders, including researchers, healthcare professionals, service providers, regulatory agencies, government, investors , pharma and biotech companies, patients and patient advocacy groups. In times like these, effective collaboration between the various stakeholders in the oncology ecosystem could offer immense benefits.
Lumiseek helps to integrate the requirements of all stakeholders, reduce duplication of efforts, cuts the time-to-market and even bring down the costs. It streamlines communication primarily across three broad categories of finding collaborators with complementary expertise, establishing and managing global collaborative projects, and managing your professional network by strategically grouping and segregating shared communication. Lumiseek registers qualified cancer-focused organizations of all types and has mechanisms to securely and privately communicate with them to develop a synergy with their near-term goals. Because Lumiseek is developed by professionals with extensive experience across most functions of the cancer care value chain, all the requirements of various stakeholders in the field of oncology have been considered and incorporated into the platform.
Dec 10, 2019
View more→